Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,
We have written a number of articles that we hope will be of interest to you. This includes health guides for various medical conditions; news about drug development and regulatory issues related to Health Canada and the FDA; and other health-related topics. Clicking on the title of a Health Guide will take you to information on that medical condition. Or click on one of the listed topics, such as Industry News or Diabetes. You can also access recent articles by scrolling down the page or clicking an article under ‘Recent Articles’.